← All trials
NCT04841811
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2021
- Primary completion
- Oct 15, 2022
- Completion date
- Aug 15, 2024
- First posted
- Apr 12, 2021
- Last posted
- Apr 12, 2021
- Enrollment
- 156
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangdong Association of Clinical TrialsLead sponsor
- Fudan UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Anhui Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- Wuhan UniversityOverall official - principal investigator
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Collaborator
- Jiangxi Provincial Cancer HospitalOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- Cancer Hospital of Yunnan provincealOverall official - principal investigator
- Henan Provincial Cancer HospitalOverall official - principal investigator
- Huai'an First People's HospitalOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Shaanxi Provincial People's HospitalOverall official - principal investigator
- Nanjing UniversityOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Shandong Provincial Cancer HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.